Summary
This 8-K filing from Edwards Lifesciences Corporation (EW) on July 20, 2009, primarily announces the company's financial results for the second quarter of 2009. The report itself is brief, serving as a cover for a press release containing the detailed financial information. Investors should refer to the attached press release (Exhibit 99.1) for specifics on revenue, earnings, and any forward-looking guidance. While the 8-K does not contain the financial data directly, its purpose is to officially disseminate this information to the market. Key takeaways for investors will be within the press release, likely covering performance against expectations, segment performance (e.g., heart valves, critical care), and any updates on strategic initiatives or challenges faced during the quarter. The filing emphasizes that the press release information is furnished, not officially filed, meaning it's for informational purposes and doesn't carry the same legal implications as a fully filed document.
Key Highlights
- 1Edwards Lifesciences announced its second quarter 2009 financial results on July 20, 2009.
- 2The 8-K filing serves as a cover for a press release containing the Q2 2009 financial results.
- 3Investors need to consult the accompanying press release (Exhibit 99.1) for detailed financial performance data.
- 4The filing is an "Item 2.02" disclosure, related to Results of Operations and Financial Condition.
- 5The Chief Financial Officer, Thomas M. Abate, signed the report.
- 6The information furnished under Item 2.02 is not deemed 'filed' for purposes of the Securities Exchange Act of 1934.